二甲双胍联合吡格列酮在治疗肥胖2型糖尿病患者中的应用

目的观察二甲双胍联合吡格列酮在治疗肥胖2型糖尿病（T2DM）患者中的临床疗效。方法2008年1月-2009年1月,84例肥胖T2DM患者随机分为观察组和对照组,每组42例。观察组采用二甲双胍联合吡格列酮治疗,对照者单纯采用二甲双胍治疗,观察两组血糖、胰岛素及血脂水平的变化。结果治疗后两组FPG、2hPG、FINS及P2 INS水平均明显下降,与治疗前比较差异有统计学意义（P〈0.05）。观察组治疗后FPG、2hPG、FINS及P2 INS水平均低于同期对照组水平,两组比较差异有统计学意义（P〈0.05）。两组治疗后TC、TG及LDL-C水平略有下降,而HDL-C水平略有升高,但与治疗前比较差异均无统计学意义（P〉0.05）。结论二甲双胍联合吡格列酮可降低肥胖T2DM患者血糖、胰岛素水平,是治疗2型糖尿病肥胖患者理想的方法。

The application of metformin combined with pioglitazone in treatment with obesity type 2 diabetes patients

Objective To observe the clinical effects of metformin combined with pioglitazone in treatment with obesity type 2 diabetes （T2DM） patients. Methods From January 2008 to January 2009, 84 cases of obesity T2DM patients were randomly classified into two groups, which observation group were treated with metformin combined with pioglitazone and control group were treated with metformin. The blood sugar, insulin and blood fat were observed. Results Compared with pre-treatment, the FPG, 2hPG, FINS and P2INS were significantly increased（P〈0. 05 ）after treatment in two groups. Moreover, the FPG, 2hPG, FINS and P2INS in observation group were significantly lower than those in control group（P〈0. 05）. There were no significantly differences in TC, TG, HDL-C and LDL-C between pre-treatment and pro-treatment（ P〉0.05 ）. Conclusion metformin combined with pioglitazone can decrease blood sugar and insulin levels, which is a idea method in treatment with obesity T2DM patients.